![ESMO distinguishes Diana Martins (IPATIMUP) with the "Best Poster Award" in the category of Breast Cancer | ASPIC ESMO distinguishes Diana Martins (IPATIMUP) with the "Best Poster Award" in the category of Breast Cancer | ASPIC](https://www.aspic.pt/sites/default/files/styles/node_detail/public/field/image/news-dianamartinsESMO.png?itok=9MObMZ5p)
ESMO distinguishes Diana Martins (IPATIMUP) with the "Best Poster Award" in the category of Breast Cancer | ASPIC
![Bugworks Research Inc. to Present Poster at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023, in Geneva, Switzerland Bugworks Research Inc. to Present Poster at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023, in Geneva, Switzerland](https://mma.prnewswire.com/media/2293179/Bugworks_Logo.jpg)
Bugworks Research Inc. to Present Poster at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023, in Geneva, Switzerland
![Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting - anaveon Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting - anaveon](https://anaveon.com/wp-content/uploads/2023/10/023-10-23-ESMO-2023-poster-ANV419-001-.png)
Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting - anaveon
![DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH](https://www.dontbepatient.com/dbp-data/uploads/esmo22.jpg)
DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH
![ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)](https://www.urotoday.com/images/stories/conferences/esmo/esmo_2014_P12-2-poster_final.jpg)
ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
![VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines](https://www.vbivaccines.com/wp-content/uploads/2020/09/ESMO-2020-Poster.png)